LPD-824


N-Pyrrolidyllysergamide, also known as lysergic acid pyrrolidide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide. It is the analogue of LSD in which the N,''N-diethylamide moiety has been cyclized into an N'',N-pyrrolidide ring.

Use and effects

The drug has been reported to have mild and relatively short-lasting LSD-like effects in humans at an oral dose of 800μg equivalent to one-tenth this amount of LSD. Based on different clinical studies, it is estimated to be 5 to 10% as potent as LSD in humans. Its duration was shorter than that of LSD, lasting around 5hours as opposed to 7hours in the case of LSD. The drug produced nausea at small doses in humans, which was dose-limiting in terms of evaluating its effects.

Interactions

Pharmacology

Pharmacodynamics

LPD-824 is known to be a serotonin receptor modulator, including of the serotonin 5-HT2A receptor, where it acted as a partial agonist with about 17-fold lower potency than LSD but an efficacy slightly higher than that of LSD in terms of phosphatidylinositol hydrolysis. It also showed affinities for the serotonin 5-HT2C and 5-HT1A receptors similar to those of LSD.
It had about 5 to 10% of the potency of LSD in preclinical studies with animals, for instance in terms of serotonin antagonism in the rat uterus and hyperthermia in rabbits. It is described as a very strong hypotensive agent in animals. In subsequent rodent drug discrimination tests, LPD-824 fully substituted for LSD, albeit with only about 16 to 25% of the potency.

History

LPD-824 was first described in the scientific literature by Albert Hofmann and colleagues by 1955.

Society and culture

Legal status

Canada

LPD-824 is not a controlled substance in Canada as of 2025.

United States

LPD-824 is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.